by Norman L. Weinberg
The pharmaceutical industry, with annual worldwide sales of more than $200 billion, has for many years provided a wealth of opportunities for organic electrosynthesis of high value added intermediates. Many of these are now commercial. The most exciting R&D is occurring in electrosynthesis of chiral drug intermediates. These are enantiomerically pure single isomers of a mixture of possible diastereomers.